Medicare Enrolled
Dr. Vinu Madhusudanannair Kunnuparampil, M.D.
Hospice and Palliative Medicine (Internal Medicine) Physician · San Antonio, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Madhusudanannair Kunnuparampil from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Madhusudanannair Kunnuparampil?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Madhusudanannair Kunnuparampil
Dr. Vinu Madhusudanannair Kunnuparampil is a hospice and palliative medicine physician in San Antonio, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Madhusudanannair Kunnuparampil performed 87,110 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Madhusudanannair Kunnuparampil received a total of $13,748 from 69 pharmaceutical and/or device companies across 418 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Madhusudanannair Kunnuparampil is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years of NPI registration
▲ Top 2% volume in TX
$13,748 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗87,110
Medicare services
Top 2% in TX for hospice and palliative medicine (internal medicine) physician
Not available
Unique patients (not deduplicated)
$4
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
72,750 | $1 | $3 |
| Denosumab injection (Prolia/Xgeva) | 6,060 | $19 | $72 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,624 | $0 | $0 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
1,620 | $6 | $23 |
| Anti-nausea injection (ondansetron/Zofran) | 600 | $0 | $2 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
524 | $8 | $23 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
473 | $10 | $32 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
391 | $8 | $15 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
365 | $22 | $86 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
213 | $97 | $376 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
171 | $11 | $47 |
| Iron level test | 166 | $6 | $19 |
| Iron binding capacity test A blood test that measures the amount of iron in the blood and the blood's ability to bind and transport iron. |
166 | $9 | $26 |
| Ferritin level test (iron stores) A blood test that measures the level of ferritin, a protein that stores iron in the body. |
164 | $13 | $41 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
160 | $48 | $185 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
160 | $90 | $372 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
135 | $12 | $58 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
133 | $21 | $90 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
129 | $66 | $263 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
112 | $15 | $60 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
96 | $1 | $3 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
82 | $1 | $1 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
80 | $130 | $523 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
80 | $58 | $232 |
| Complete blood count (CBC), automated An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood. |
76 | $6 | $19 |
| Lactate dehydrogenase (LDH) level test A blood test that measures the amount of lactate dehydrogenase, an enzyme found in many body tissues. It helps assess tissue damage or disease. |
69 | $6 | $18 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
69 | $48 | $205 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 65 | $339 | $1,298 |
| PSA test (prostate cancer screening) | 51 | $18 | $55 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
44 | $4 | $17 |
| Magnesium level test A blood test to measure the amount of magnesium in your body. This helps check for magnesium deficiency or excess. |
41 | $7 | $20 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
38 | $116 | $485 |
| Carcinoembryonic antigen (CEA) level test A blood test that measures the level of carcinoembryonic antigen (CEA) protein. This test is used to monitor certain types of cancer. |
34 | $19 | $57 |
| New patient office visit, complex (60-74 min) | 34 | $151 | $641 |
| Vitamin B-12 level test A blood test that measures the amount of vitamin B-12 in your body. |
31 | $15 | $45 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
29 | $91 | $349 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
27 | $99 | $482 |
| Immunoglobulin level test A blood test that measures the level of gammaglobulins, which are immune system proteins. |
21 | $9 | $28 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 16 | $20 | $62 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
11 | $133 | $574 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
84.6% high complexity
12.1% medium
3.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$13,748
Total received (2018-2024)
Avg $1,964/year across 7 years
Top 4% in TX for hospice and palliative medicine (internal medicine) physician
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
69
Companies
418
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$8,505
2023
$2,504
2022
$1,023
2021
$679
2020
$52
2019
$24
2018
$960
Payments by company (2024)
Deciphera Pharmaceuticals Inc.
$3,973
Daiichi Sankyo Inc.
$607
Merck Sharp & Dohme LLC
$359
Novartis Pharmaceuticals Corporation
$316
E.R. Squibb & Sons, L.L.C.
$299
Takeda Pharmaceuticals U.S.A., Inc.
$281
Janssen Biotech, Inc.
$276
AstraZeneca Pharmaceuticals LP
$271
Celgene Corporation
$159
Incyte Corporation
$158
Bayer Healthcare Pharmaceuticals Inc.
$132
Genentech USA, Inc.
$129
GENZYME CORPORATION
$113
Ipsen Biopharmaceuticals, Inc
$106
Eisai Inc.
$90
JAZZ PHARMACEUTICALS INC.
$87
PFIZER INC.
$82
Gilead Sciences, Inc.
$81
Genmab U.S., Inc.
$76
GlaxoSmithKline, LLC.
$61
Lilly USA, LLC
$61
Myriad Genetic Laboratories, Inc.
$60
Alexion Pharmaceuticals, Inc.
$59
Regeneron Healthcare Solutions, Inc.
$55
Apellis Pharmaceuticals, Inc.
$55
ABBVIE INC.
$45
Stemline Therapeutics Inc.
$40
SERVIER PHARMACEUTICALS LLC
$37
EMD Serono, Inc.
$37
ADC Therapeutics America, Inc.
$36
Spectrum Pharmaceuticals Inc.
$36
Tempus AI, Inc
$32
Janssen Pharmaceuticals, Inc
$26
Kite Pharma, Inc.
$25
SOBI, INC
$23
Sumitomo Pharma America, Inc.
$22
Astellas Pharma US Inc
$22
Mirati Therapeutics, Inc.
$22
TAIHO ONCOLOGY, INC.
$22
Sirtex Medical Inc
$21
Iovance Biotherapeutics, Inc.
$21
Karyopharm Therapeutics Inc.
$20
Rigel Pharmaceuticals, Inc.
$15
Exelixis Inc.
$15
Blueprint Medicines Corporation
$14
Agios Pharmaceuticals, Inc.
$13
Azurity Pharmaceuticals, Inc.
$13
Top 3 companies account for 58.1% of 2024 payments
All-time payments by company (2018-2024) ›
Deciphera Pharmaceuticals Inc.
$4,019
Novartis Pharmaceuticals Corporation
$828
Daiichi Sankyo Inc.
$762
Merck Sharp & Dohme LLC
$581
E.R. Squibb & Sons, L.L.C.
$497
Genentech USA, Inc.
$493
Celgene Corporation
$456
AstraZeneca Pharmaceuticals LP
$443
Amgen Inc.
$423
Janssen Biotech, Inc.
$415
PFIZER INC.
$366
GENZYME CORPORATION
$360
Takeda Pharmaceuticals U.S.A., Inc.
$337
Incyte Corporation
$231
GlaxoSmithKline, LLC.
$177
JAZZ PHARMACEUTICALS INC.
$173
Eisai Inc.
$170
Ipsen Biopharmaceuticals, Inc
$161
Bayer Healthcare Pharmaceuticals Inc.
$147
Janssen Pharmaceuticals, Inc
$140
Pharmacosmos Therapeutics Inc.
$125
Lilly USA, LLC
$123
Apellis Pharmaceuticals, Inc.
$107
Karyopharm Therapeutics Inc.
$104
Janssen Scientific Affairs, LLC
$99
Gilead Sciences, Inc.
$99
Genmab U.S., Inc.
$97
ABBVIE INC.
$92
SOBI, INC
$92
ADC Therapeutics America, Inc.
$87
Rigel Pharmaceuticals, Inc.
$86
MorphoSys, US Inc.
$81
Alexion Pharmaceuticals, Inc.
$79
Merck Sharp & Dohme Corporation
$71
Stemline Therapeutics Inc.
$64
Myriad Genetic Laboratories, Inc.
$60
Mirati Therapeutics, Inc.
$58
Immunocore Limited
$57
Agios Pharmaceuticals, Inc.
$57
Regeneron Healthcare Solutions, Inc.
$55
EMD Serono, Inc.
$55
Sumitomo Pharma America, Inc.
$51
Blueprint Medicines Corporation
$51
AVEO Pharmaceuticals, Inc.
$49
Kite Pharma, Inc.
$47
PharmaEssentia USA Corporation
$44
Astellas Pharma US Inc
$43
TAIHO ONCOLOGY, INC.
$41
EISAI INC.
$39
Seagen Inc.
$38
SERVIER PHARMACEUTICALS LLC
$37
Pharmacyclics LLC, An AbbVie Company
$36
Spectrum Pharmaceuticals Inc.
$36
Tempus AI, Inc
$32
CTI BioPharma Corp.
$24
ARRAY BIOPHARMA INC
$22
Kyowa Kirin, Inc.
$21
Sirtex Medical Inc
$21
Iovance Biotherapeutics, Inc.
$21
Sobi, Inc
$21
Seattle Genetics, Inc.
$20
RECORDATI_RARE_DISEASES_INC.
$20
PUMA BIOTECHNOLOGY, INC.
$18
Jazz Pharmaceuticals Inc.
$16
Secura Bio, Inc.
$16
Exelixis Inc.
$15
Epizyme, Inc.,
$15
SANOFI-AVENTIS U.S. LLC
$14
Azurity Pharmaceuticals, Inc.
$13
Top 3 companies account for 40.8% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · ALUNBRIG · AUGTYRO · AYVAKIT · Amtagvi · Avastin · BAVENCIO · BESREMI · BLENREP · BOSULIF · BRAFTOVI · CABLIVI · CABOMETYX · CARVYKTI · COPIKTRA · CYRAMZA · Columvi · DARZALEX · DOPTELET · Doptelet · ELITEK · ENHERTU · ENJAYMO · ERLEADA · Empaveli · Enhertu · Epkinly · Erleada · FOTIVDA · FRUZAQLA · Fabhalta · Gazyva · IBRANCE · ICLUSIG · IMBRUVICA · INJECTAFER · INLYTA · Imbruvica · JADENU · JAKAFI · JEVTANA · KEYTRUDA · KIMMTRAK · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LUMAKRAS · LYNPARZA · Lenvima · MEKINIST · MONJUVI · MONOFERRIC · MYRISK · NERLYNX · NINLARO · Neulasta · Nplate · Nubeqa · OJJAARA · OPDIVO · OPDUALAG · ORGOVYX · Onivyde · Orserdu · PADCEV · PLUVICTO · POLIVY · POTELIGEO · PRECISETUMOR · PROMACTA · PYRUKYND · Perjeta · Pomalyst · QINLOCK · REBLOZYL · ROLVEDON · RYBREVANT · RYDAPT · Revlimid · Rezlidhia · SARCLISA · SCEMBLIX · SHINGRIX · SIR-Spheres Microspheres · SOLIRIS · SUNOSI · SYLVANT · Somatuline Depot · Stivarga · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · Tecentriq · Tibsovo · Trodelvy · ULTOMIRIS · VENCLEXTA · VERZENIO · VIMSELTINIB · VIVIMUSTA · Venclexta · Vonjo · WELIREG · XALKORI · XARELTO · XGEVA · XOSPATA · XPOVIO · Yescarta · ZEPZELCA
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Hospice and palliative medicine physicians in nearby ZIP areas
14
County median income
$70,571
Nearest hospital to ZIP centroid (approximate)
UNIVERSITY HEALTH SYSTEM
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Madhusudanannair Kunnuparampil is a mixed practice specialist, with above-average Medicare volume (top 2% in TX), with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Madhusudanannair Kunnuparampil experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Madhusudanannair Kunnuparampil performed 72,750 iron infusion (injectafer) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Madhusudanannair Kunnuparampil receive payments from pharmaceutical companies?
Yes. Dr. Madhusudanannair Kunnuparampil received a total of $13,748 from 69 companies across 418 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Madhusudanannair Kunnuparampil's costs compare to other hospice and palliative medicine physicians in San Antonio?
Dr. Madhusudanannair Kunnuparampil's average Medicare payment per service is $4. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Madhusudanannair Kunnuparampil) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Hospice And Palliative Medicine Physicians in San Antonio
Browse hospice and palliative medicine physicians in San Antonio ranked by procedure volume and transparency data.
Highest volume
Top Hospice And Palliative Medicine Physicians in TX
Hospice and palliative medicine physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hospice And Palliative Medicine Physicians in TX
Which TX hospice and palliative medicine physicians receive the most from drug and device companies.
By company
Deciphera Pharmaceuticals Inc. Payments to Doctors
See all physicians who received payments from Deciphera Pharmaceuticals Inc.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Daiichi Sankyo Inc. Payments to Doctors
See all physicians who received payments from Daiichi Sankyo Inc.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology